Effect of interleukin-17A inhibitor in Japanese patients with psoriatic arthritis compared with tumor necrosis factor-alpha inhibitor.
OBJECTIVES
The patient of severe psoriatic arthritis (PsA) is mainly treated with oral methotrexate, ciclosporin, and anti-tumor necrosis factor-alpha inhibitors (TNFi). Recently, anti-interleukin-17A inhibitors (IL-17Ai) have been used in the treatment of PsA. This study aimed to evaluate the efficacy and safety of IL-17Ai in Japanese patients with PsA compared with those of TNFi.


METHODS
This was a longitudinal and retrospective study. The study population included 31 Japanese patients with PsA. All enrolled patients fulfilled the Classification Criteria for Psoriatic Arthritis. All patients were treated with TNFi or IL-17Ai. The assessed clinical manifestations were C-reactive protein (CRP)-based Disease Activity Score in 28 Joints (DAS28-CRP), disease activity in psoriatic arthritis (DAPSA), 20% achievement of American College of Rheumatology core set, swollen joint count (SJC), tender joint count (TJC), and visual analog scale (VAS). Functional ability of patients with PsA was analyzed using the modified health assessment questionnaire (mHAQ) score. We evaluated the parameters at baseline and weeks 12, 24, and 52.


RESULTS
The change in SJC, TJC, VAS, mHAQ, and DAPSA had no significant difference at weeks 12, 24, and 52. The improvements of CRP and DAS28-CRP were significantly higher in TNFi group only at week 12. The biologics retention rate was significantly higher in TNFi group by the log-rank test. No critical adverse events occurred.


CONCLUSIONS
Our study presented that IL-17Ai had treatment effects comparable to TNFi. IL-17Ai might have the potential to become an alternative to the previous drug, but more large-scale studies are expected.
['Izumiyama|Takuya|T|0000-0001-6163-4048', 'Mori|Yu|Y|', 'Oizumi|Itsuki|I|', 'Hamada|Soshi|S|', 'Kurishima|Hiroaki|H|', 'Terui|Hitoshi|H|0000-0002-7598-2833', 'Omori-Shimada|Ryoko|R|', 'Yamasaki|Kenshi|K|', 'Itoi|Eiji|E|']
D000328:Adult D000911:Antibodies, Monoclonal D018501:Antirheumatic Agents D015535:Arthritis, Psoriatic D005260:Female D006801:Humans D020381:Interleukin-17 D007564:Japan D008137:Longitudinal Studies D008297:Male D008727:Methotrexate D008875:Middle Aged D012074:Remission Induction D012189:Retrospective Studies D016896:Treatment Outcome D014409:Tumor Necrosis Factor-alpha
psoriatic arthritis anti-tumor necrosis factor-alpha inhibitor anti-interleukin-17A inhibitor treatment effects